Shares of Orchid Pharma were locked in a 10 per cent lower circuit at Rs 1,187.85 on the BSE on Thursday as the company’s two-day stake sale through an offer for sale (OFS) began today. The floor price for the offer has been fixed at Rs 375 a share.
Dhanuka Laboratories, one of the promoters of Orchid Pharma, proposed to sell in aggregate up to 3.28 million equity shares, representing 8.04 per cent of the total equity share capital of the Company. The issue opened today for non-retail investors and will open for retail investors on Friday.
The sale is being undertaken by the seller, among other things, for achieving the minimum public shareholding, the company said in its notice to exchanges. As of March 31, 2021, the promoters held a 98.04 per cent stake in Orchid Pharma, the shareholding pattern data shows.
- GIFT Nifty Surges as Donald Trump’s 90-Day Tariff Freeze Boosts Sentiment
- Biocon Subsidiary Secures USFDA Approval
- Aurobindo Pharma Arm Completes Phase 1 Trials of New Bone Medicine
- China’s Central Bank Urges State Lenders to Cut Dollar Buying
- India Approves Rs 63,000 Crore Deal for 26 Rafale Marine Jets from France
Orchid Pharma is a pioneer in Cephalosporin Antibiotics, R&D focused inventor of Enmetazobactam (Ph.-3 Trials done in US & EU) acquired by Dhanuka Group through Corporate Insolvency Resolution Process (CIRP) process on April 1, 2020.
Stock Covered in the news
